Literature DB >> 15131534

Impaired glucose tolerance and cardiovascular disease: the possible role of post-prandial hyperglycemia.

Antonio Ceriello1.   

Abstract

There is increasing evidence that the post-prandial state is an important contributing factor in the development of atherosclerosis. In subjects with impaired glucose tolerance, whereas fasting glycemia is in reference range, the post-prandial phase is characterized by a rapid and large increase in blood glucose levels. The possibility that this post-prandial "hyperglycemic spike" may be relevant to the development of cardiovascular disease in these subjects has received recently much attention. The oral glucose tolerance test, although highly non-physiological, has been used largely as model of the post-prandial state, and epidemiological studies have shown that impaired oral glucose tolerance is associated with an increased risk of cardiovascular disease, because the glycemia level after 2 hours of the glucose challenge is a direct and independent risk factor. Most of the cardiovascular risk factors are modified in the post-prandial phase and are directly affected by an acute increase of glycemia. The mechanisms through which acute hyperglycemia exerts its effects may be identified in the production of free radicals, which favours the development of an endothelial dysfunction, a prothrombotic and proinflammatory condition. Future studies may evaluate whether correcting the post-prandial hyperglycemia in the impaired glucose tolerance state can form part of the strategy for the prevention and management of cardiovascular diseases in these subjects.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15131534     DOI: 10.1016/j.ahj.2003.11.020

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  25 in total

1.  Enhanced proliferation and migration of vascular smooth muscle cells in response to vascular injury under hyperglycemic conditions is controlled by beta3 integrin signaling.

Authors:  Manikandan Panchatcharam; Sumitra Miriyala; Fanmuyi Yang; Michael Leitges; Magdalena Chrzanowska-Wodnicka; Lawrence A Quilliam; Paul Anaya; Andrew J Morris; Susan S Smyth
Journal:  Int J Biochem Cell Biol       Date:  2010-02-23       Impact factor: 5.085

2.  Glucose tolerance is negatively associated with circulating progenitor cell levels.

Authors:  G P Fadini; L Pucci; R Vanacore; I Baesso; G Penno; A Balbarini; R Di Stefano; R Miccoli; S de Kreutzenberg; A Coracina; A Tiengo; C Agostini; S Del Prato; A Avogaro
Journal:  Diabetologia       Date:  2007-06-20       Impact factor: 10.122

3.  Glutathione deficiency down-regulates hepatic lipogenesis in rats.

Authors:  Corinna Brandsch; Tobias Schmidt; Diana Behn; Kristin Weisse; Andreas S Mueller; Gabriele I Stangl
Journal:  Lipids Health Dis       Date:  2010-05-19       Impact factor: 3.876

4.  Role of diabetes, hypertension, and cigarette smoking on atherosclerosis.

Authors:  Ram K Mathur
Journal:  J Cardiovasc Dis Res       Date:  2010-04

5.  Cardiometabolic risk management in type 2 diabetes and obesity.

Authors:  Angela M Taylor
Journal:  Curr Diab Rep       Date:  2008-10       Impact factor: 4.810

6.  Postchallenge responses of nitrotyrosine and TNF-alpha during 75-g oral glucose tolerance test are associated with the presence of coronary artery diseases in patients with prediabetes.

Authors:  Chih-Sheng Chu; Kun-Tai Lee; Kai-Hong Cheng; Min-Yi Lee; Hsuan-Fu Kuo; Tsung-Hsien Lin; Ho-Ming Su; Wen-Chol Voon; Sheng-Hsiung Sheu; Wen-Ter Lai
Journal:  Cardiovasc Diabetol       Date:  2012-03-07       Impact factor: 9.951

7.  Bath Breakfast Project (BBP)--examining the role of extended daily fasting in human energy balance and associated health outcomes: study protocol for a randomised controlled trial [ISRCTN31521726].

Authors:  James A Betts; Dylan Thompson; Judith D Richardson; Enhad A Chowdhury; Matthew Jeans; Geoffrey D Holman; Kostas Tsintzas
Journal:  Trials       Date:  2011-07-08       Impact factor: 2.279

8.  Effect of repaglinide on endothelial dysfunction during a glucose tolerance test in subjects with impaired glucose tolerance.

Authors:  Isabella Schmoelzer; Thomas C Wascher
Journal:  Cardiovasc Diabetol       Date:  2006-04-10       Impact factor: 9.951

9.  A randomized, double blind, cross-over, placebo-controlled clinical trial to assess the effects of Candesartan on the insulin sensitivity on non diabetic, non hypertense subjects with dysglyce mia and abdominal obesity. "ARAMIA".

Authors:  Patricio López-Jaramillo; Lina P Pradilla; Vicente Lahera; Federico A Silva Sieger; Christian F Rueda-Clausen; Gustavo A Márquez
Journal:  Trials       Date:  2006-09-07       Impact factor: 2.279

10.  Postprandial glucose improves the risk prediction of cardiovascular death beyond the metabolic syndrome in the nondiabetic population.

Authors:  Hung-Ju Lin; Bai-Chin Lee; Yi-Lwun Ho; Yen-Hung Lin; Ching-Yi Chen; Hsiu-Ching Hsu; Mao-Shin Lin; Kuo-Liong Chien; Ming-Fong Chen
Journal:  Diabetes Care       Date:  2009-06-05       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.